The National Psoriasis Foundation (NPF) announced in a press release that the Centers for Medicare and Medicaid Services will not cut reimbursement for phototherapy in 2015.
Many studies that inform current international guidelines for the treatment of psoriatic arthritis (PsA) are of poor quality and lack applicability in clinical practice.
The US Food and Drug Administration recently announced its approval of a new medication for the treatment of rheumatoid arthritis.
For patients with moderate-to-severe plaque psoriasis, the fully human anti-interleukin-17A monoclonal antibody, secukinumab, is effective, according to research published online July 9 in the New England Journal of Medicine.
Individuals with hypertension and those with long-term, regular use of beta-blocker medication may be at increased risk of developing psoriasis flares, according to research published online July 2 in JAMA Dermatology.
Study results show that treatment with etanercept is effective and well tolerated in adolescent patients with psoriatic arthritis and other rheumatic conditions.